Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5417.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baines, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Baines, A. J.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Next Article next article arrow

InsideBlood

RED CELLS

Comment on Gaetani et al, page 5712

Mechanisms of elliptocytosis: significant spectrin substitutions

Anthony J. Baines

UNIVERSITY OF KENT

In this issue of Blood, Gaetani and colleagues provide an analysis of mutations in {alpha}-spectrin that give rise to HE and HPP. Their results indicate a biochemical basis for mutations in a single gene giving rise to such widely varying clinical phenotypes.

Hereditary elliptocytosis (HE) has an estimated incidence in the United States of 3 to 5 members of the population per 10 000. The most common mutations underlying the disease are in the SPTA1 gene, which encodes {alpha}I-spectrin.1 Clinically, the phenotype is very variable, ranging from asymptomatic (where the diagnosis may only come about adventitiously upon examination of a blood film) to severe hemolytic anemia. A related condition, hereditary pyropoikilocytosis (HPP), is in effect an aggravated form of HE. So, how do mutations in a single gene give rise to such a wide spectrum of outcomes?

It is more than 2 decades since spectrin mutations were first associated with HE. Since then, numerous mutations in SPTA1 have been identified in cases of HE and HPP.1 Many of these change an amino acid at the {alpha}I-spectrin site that binds to βI-spectrin in the formation of spectrin tetramers. Spectrin tetramers are the functional units that provide resistance to shear stresses in circulation.2 Gaetani and colleagues engineered 14 different mutations into recombinant fragments of {alpha}I-spectrin (see figure). They then used microcalorimetry, an exquisitely sensitive technique that measures the heat changes associated with binding between proteins, to quantify the binding of the mutants to fragments of βI-spectrin. Their results indicate that different mutations have very different effects on affinity. For example, changing arginine 34 to tryptophan (R34W) has little or no effect on affinity of interaction. In contrast, 5 other mutants completely lost detectable binding activity. The remaining mutations exhibited reductions in affinity, but not complete loss of binding. Gaetani et al also analyzed the recombinant proteins for evidence of gross structural changes, and found none. They concluded that HE and HPP arising from these mutations result from changes in molecular recognition between spectrin subunits rather than structural alterations.


Figure 1
View larger version (71K):
[in this window]
[in a new window]

 
The structure of the N-terminal region of {alpha}I-spectrin. The figure is drawn from Protein Databank entry 1OWA. The first helix of {alpha}I-spectrin interacts with β in forming spectrin tetramers. In the accompanying paper, Gaetani et al describe the mechanisms by which mutations in residues I24, R28, and R45 (among others) cause hereditary elliptocytosis. In the cases of the residues indicated, pathogenic mutations eliminate interaction with β-spectrin. Illustration by Anthony Baines and Debra Tyler.

 
One of the intriguing questions raised by the current study is whether mutations such as R34W, which cause little or no change in molecular recognition and yet are associated with the disease, are actually pathogenic. The authors suggest that perhaps their assay does not detect all the critical changes in molecular activity. For instance, the R34W mutation was originally found in trans with a low expression polymorphism, {alpha}LELY. The combined mutations might sufficiently reduce spectrin activity in situ to produce HE. Alternatively (or in addition), there may be further mutations that were not picked up in the original analyses of the patients concerned.

The data reported here also contrast with a separate case of HE analyzed by Johnson et al3 in another recent paper in Blood. In this case, the pathogenic mutation was not in the tetramerization site, but was located much further away in the body of the {alpha}I-spectrin polypeptide. The effect of the mutation was revealed in the stability of protein folding. So, HE/HPP can arise from more than one class of mechanism.

Gaetani et al conclude that mutations that abolish binding of {alpha}-spectrin to β-spectrin are at sites highly conserved across all spectrins, even in simple invertebrates. In this respect, the red-cell membrane continues to live up to its traditional role of illuminating processes essential to the function of membranes in all animals.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Gallagher PG. Hereditary elliptocytosis: Spectrin and protein 4.1R. Semin Hematol. 2004;41:142–164.[CrossRef][Medline] [Order article via Infotrieve]

  2. An X, Lecomte MC, Chasis JA, Mohandas N, Gratzer W. Shear-response of the spectrin dimer-tetramer equilibrium in the red blood cell membrane. J Biol Chem. 2002;277:31796–31800.[Abstract/Free Full Text]

  3. Johnson CP, Gaetani M, Ortiz V, et al. Pathogenic proline mutation in the linker between spectrin repeats: disease caused by spectrin unfolding. Blood. 2007;109:3538–3543.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Structural and functional effects of hereditary hemolytic anemia-associated point mutations in the alpha spectrin tetramer site
Massimiliano Gaetani, Sara Mootien, Sandra Harper, Patrick G. Gallagher, and David W. Speicher
Blood 2008 111: 5712-5720. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baines, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Baines, A. J.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020